p73 started off as an ugly duckling-a false positive specific transactivator, which probably requires oligocDNA clone in a screen for mediators of insulin signaling merization, and is likely to regulate genes that at least (Kaghad et al., 1997) . However, as soon as its sequence partially overlap those targeted by p53. Strong support was obtained, its swan-like charm emerged.
exists for some, though presently not all, of these predicp73-A Structural and Functional Homolog of p53 tions. Analysis by the yeast two-hybrid assay revealed The last decade has yielded extensive information on that p73␤ can homo-oligomerize as efficiently as p53 p53. Biologically, the best known activities of p53 are cell (Kaghad et al., 1997) . Surprisingly, perhaps, p73␣ failed growth arrest and induction of apoptosis. Both probably to form homotypic interactions. Moreover, the experirequire activation of latent p53 by incoming signals, ofments suggest a significant, albeit relatively weak, interten coupled with a substantial increase in overall cellular action between p73␤ and p53. It will be interesting to p53 levels. see whether mixed oligomers indeed exist in cells, and Human p53 comprises 393 amino acid residues (Fig- how this affects the biochemical and biological activities ure 1). It includes three main functional domains: an of p53. N-terminal acidic transactivation domain (TAD), a central More importantly, p73 overexpression can trigger at DNA-binding core domain (DBD), and a C-terminal least one canonical p53 target gene, p21
Waf1
. The p21
homo-oligomerization domain (OD). All three domains gene is strongly induced by p53 in many cell types (Elare required for efficient binding of p53 to recognition Deiry et al., 1993) . The p21 protein is a potent inhibitor sites within its physiological target genes and for tranof cyclin-dependent protein kinases-the driving motors scriptional activation of these genes.
of the cell cycle-and augmented levels of p21 halt cell Five evolutionarily conserved boxes (I to V in Figure  cycle progression. It is thus not surprising that p21 is a 1) were identified through comparison of p53 sequences key effector, though not the only one, of p53-mediated from various vertebrates. Four of these are in the central growth arrest (Figure 2 ). DNA-binding core domain. Importantly, the vast majority
As shown now, p73 overexpression also induces p21 of tumor-associated p53 missense mutations occur (Kaghad et al., 1997 ; Table 1 ). Cells transiently transwithin this core domain, often in boxes II to V. Such fected with a p73␣ expression plasmid display markedly mutant proteins usually fail to trigger transcription of elevated levels of p21, comparable to those obtained p53 target genes, resulting in loss of tumor suppressor with wild-type p53. Importantly, p21 induction is abolactivity.
ished when a single Arg residue at position 292 of p73 The newly discovered human p73 gene encodes two is mutated to His; this residue is analogous to Arg 273 distinct polypeptides (Figure 1) . The longer one, denoted p73␣, comprises 636 residues. The shorter form, deof human p53, which is often mutated in human cancer and whose conversion to His abrogates the ability of p53 noted p73␤, arises through alternative splicing of the to activate relevant target genes. Hence, p73 appears to p73-A Long Sought-after Tumor Suppressor Gene?
The similarity to p53 provided one provocative clue that duplicate faithfully the transcriptional function of p53 on at least one critical target gene.
p73 may be a new tumor suppressor gene. The other clue came when the p73 gene was mapped to the subGiven the centrality of p21 in the p53 pathway ( Figure  2 ), it was not surprising that, like p53, p73 is also capable telomeric p36 region of human chromosome 1 (Kaghad et al., 1997) . Deletions near the tip of the short arm of of blocking cell proliferation when overexpressed. In a standard stable transfection assay, p73 effectively chromosome 1, spanning 1p36, are common in a variety of human tumors including neuroblastoma, colon canblocked colony formation (Kaghad et al., 1997 ; Table 1 ). This can be taken as preliminary evidence that p73 has cer, melanoma, and breast cancer (Schwab et al., 1996) . This observation has spurred an intensive search for attributes of a tumor suppressor, at least in this in vitro assay.
tumor suppressor genes in this chromosomal region. Recent studies suggest that this region contains at least Induction of apoptosis by p53 is less well understood. Most probably, it also involves activities of p53 distinct two, and perhaps more, distinct tumor suppressor genes (Versteeg et al., 1995; Schwab et al., 1996) . One from transactivation of specific target genes (Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997) . At putative tumor suppressor gene appears to be selectively deleted and presumably inactivated in neuropresent, it is impossible to tell whether p73 also possesses such activities (Table 1) . Nevertheless, tranblastomas that harbor amplification of the N-myc protooncogene . Such tumors typically scriptional activation does play an important part in p53-mediated apoptosis; genes that may serve as display large deletions in 1p; the critical tumor suppressor gene appears to reside in region 1p35-36.1, proximal downstream effectors have been identified (Figure 2 ). It is conceivable that the ability of p73 to up-regulate p53 to the position of p73. Even more interesting, however, is a second putative tumor suppressor gene, identified target genes is not limited to p21. Obvious questions are whether p73 can up-regulate apoptosis-related genes in neuroblastoma tumors lacking N-myc amplification. It has been tentatively mapped to 1p36.2-3, within an such as bax and Fas/Apo1, and whether p73 overexpression can cause apoptosis.
8 megabase (Mb) region. Importantly, p73 also resides in this same region. A particular feature of this putative In summary, p73 looks very much like p53, and may also work very much like p53. However, given the limited tumor suppressor gene is that it appears to be imprinted. Thus, in tumors retaining only one copy of the correamount of available data, much more needs to be done before the extent of overlap between the two can be sponding chromosomal region, this copy is almost always derived from the paternal chromosome. This critically evaluated. (Donehower et al., 1992) . Given the numerous reports Down-regulation yes ? about the role of p53 in differentiation, apoptosis, and by Mdm2
proliferation of cultured cells, the lack of dramatic devela LOH, loss of heterozygosity.
opmental phenotypes was rather disappointing. Although some defects were later uncovered, they were limited in scope and penetrance. With other key regulastrongly suggests that the paternal locus is imprinted tory proteins, mild phenotypes of single knock-outs and consequently transcriptionally silent. Thus, the loss were explained by functional redundancy with other of only the maternal copy of the gene would be sufficient family members. However, such explanation could not to practically render the cells negative for the correbe offered for p53. Not until p73, that is. It may now be sponding transcript and protein. Any serious contender proposed that p73 doubles up for p53, and only fails to for the candidate gene should therefore first be found do so under conditions of genomic damage, where a to be imprinted, and additionally be silent in tumor cells specific function of p53 becomes irreplaceable. Of note, retaining only one allele.
the main difference so far between p53 and p73 is that At least at a first approximation, p73 appears to fulfill the latter protein is neither stabilized nor activated by these requirements. First, there is clear evidence for DNA damage (Kaghad et al., 1997 ; see Figure 2 ). Hence, monoallelic expression, as is expected of an imprinted it may not play a role in monitoring genomic damage. As gene. A normally occurring polymorphism has been to the possibility that p73 substitutes for developmental identified in the noncoding region of the p73 gene functions of p53, the answer is likely to come from (Kaghad et al., 1997) . Using this polymorphism, p73 crosses between p53 and p73 knock-outs. On a cautionmRNA was analyzed in the peripheral blood cells of five ary note, now that p73 has been identified, there is no heterozygous healthy individuals; in all cases, only one compelling reason to exclude the existence of additional allele was found to be expressed, suggesting that the p53 family members. Such yet-to-be-uncovered genes other one was imprinted. Moreover, in the single case are likely to complicate the genetic analysis. so far where the origin of the p73 mRNA in normal cells
Another observation that p73 may explain is that, uncould be determined, it was derived predominantly if like most tumors, neuroblastomas very rarely carry p53 not exclusively from the maternal allele. Hence, p73 apmutations (Ohgaki et al., 1993) . It could now be proposed pears to be paternally imprinted, exactly as predicted that in the particular normal cells that give rise to neurofor the putative 1p tumor suppressor gene. Needless to blastoma it is p73, rather than p53, that performs the say, one has to be extremely reserved about information crucial tumor suppressor job. Hence, once p73 is inacticoming from such a small number of samples, regarding vated, there will be no significant selective pressure to it mainly as an incentive for obtaining more complete, inactivate p53 as well. The actual picture is, however, unequivocal data. more complex. While the p53 gene remains wild-type Analysis of tumor-derived cell lines also largely agrees in almost all neuroblastomas, the protein may be miswith the notion that p73 is a strong candidate for the placed: rather than being nuclear, it accumulates in the "real" 1p tumor suppressor gene. In particular, extremely cytoplasm (Ostermeyer et al., 1996) . It is presently conlow levels of p73 mRNA were found in the majority troversial whether this is truly a functional inactivation (4/6) of neuroblastoma cell lines harboring chromosome of p53, which blocks its ability to respond to stress 1p deletions (Kaghad et al., 1997) . This stands in stark and maintain genomic integrity. Yet, if this cytoplasmic contrast with lines derived from some other tumors and sequestration truly results in p53 incapacitation, it may from neuroblastoma without a deletion in 1p, where easmake the need to invoke p73 less obvious. Even so, one ily detectable p73 expression was much more common.
could still propose that it is the lack of functional p73 Hence, the p73 allele retained in these four neuroprotein that underlies the cytoplasmic retention of p53. blastoma lines may indeed be imprinted. Moreover, in Future work should clarify this issue. one of the two 1p deletion-positive neuroblastoma lines It is thus yet to be proven that p73 is truly the long that retained p73 mRNA, no p73 protein was detectable.
sought-after 1p tumor suppressor gene. In particular, Nevertheless, the picture is not perfect. The main disone worries about the inability to find coding region comforting observation is that despite extensive efforts, mutations in cell lines tested to date. This concern is no mutations could be found within the remaining p73 strengthened by the knowledge that single point mutaallele in tumor cells with 1p deletions. One might argue tions, analogous to those observed in p53 in human that there is no real selective pressure for mutating p73 cancer, indeed suffice to abrogate the antiproliferative if only the imprinted, nonexpressed allele is retained. effect of p73 (Kaghad et al., 1997) . Given the high freHowever, p73 is also wild-type in the one neuroblastoma quency of such mutations in p53, it is puzzling that the same does not pertain to p73 (Table 1) . While the line that expresses the protein abundantly. Clearly, if imprinted nature of the p73 locus offers a reasonable explanation, it is equally possible that p73 just happens to reside within a chromosomal region harboring a cluster of imprinted genes, and the real tumor suppressor gene may actually be one of p73's neighbors. To resolve this important issue, one may either need to eventually find some tumors, not necessarily neuroblastoma, that bear inactivating mutations in p73, or else go systematically through the entire 8 Mb region and rule out all neighboring genes one by one.
In its relatively short history, p53 research has already seen a number of surprising twists. The discovery of p73 may be another major turning point along this road. Judging from past experience, it is quite safe to predict that p73 will soon become the latest spin-off from p53 to develop into a "hot" topic in its own right.
